BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29306656)

  • 21. Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate.
    Zhang HN; He XL; Wang C; Wang Y; Chen YJ; Li JX; Niu CH; Gao P
    Pediatr Blood Cancer; 2014 Dec; 61(12):2203-7. PubMed ID: 25130190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.
    Faganel Kotnik B; Grabnar I; Bohanec Grabar P; Dolžan V; Jazbec J
    Eur J Clin Pharmacol; 2011 Oct; 67(10):993-1006. PubMed ID: 21509569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations.
    Rau T; Erney B; Göres R; Eschenhagen T; Beck J; Langer T
    Clin Pharmacol Ther; 2006 Nov; 80(5):468-76. PubMed ID: 17112803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia.
    Cheng Y; Chen MH; Zhuang Q; Lin BJ; Chen YY; Yang L; Liu MB; Que WC; Qiu HQ
    Pediatr Blood Cancer; 2021 May; 68(5):e28858. PubMed ID: 33501733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delayed Methotrexate Elimination after Administration of a Medium Dose of Methotrexate in a Patient with Genetic Variants Associated with Methotrexate Clearance.
    Tatebe Y; Kanamitsu K; Kanzaki H; Ishida H; Fujiwara K; Washio K; Kitamura Y; Sendo T; Shimada A; Tsukahara H
    Acta Med Okayama; 2020 Dec; 74(6):545-550. PubMed ID: 33361876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia.
    Liu Y; Yin Y; Sheng Q; Lu X; Wang F; Lin Z; Tian H; Xu A; Zhang J
    PLoS One; 2014; 9(1):e82681. PubMed ID: 24404132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
    Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
    Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of the frequency distribution of five single-nucleotide polymorphisms of the MTRRgene in a Chinese pediatric population with acute lymphoblastic leukemia.
    Li M; Kong XY; Wang SM
    Pharmacotherapy; 2022 Jun; 42(6):442-452. PubMed ID: 35434830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia.
    Zgheib NK; Akra-Ismail M; Aridi C; Mahfouz R; Abboud MR; Solh H; Muwakkit SA
    Pharmacogenet Genomics; 2014 Aug; 24(8):387-96. PubMed ID: 25007187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma.
    Nakano T; Kobayashi R; Matsushima S; Hori D; Yanagi M; Suzuki D; Kobayashi K
    Int J Hematol; 2021 May; 113(5):744-750. PubMed ID: 33389654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of methylenetetrahydrofolate reductase gene polymorphisms on toxicities during consolidation therapy in pediatric acute lymphoblastic leukemia in a Chinese population.
    Liu SG; Li ZG; Cui L; Gao C; Li WJ; Zhao XX
    Leuk Lymphoma; 2011 Jun; 52(6):1030-40. PubMed ID: 21534867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia.
    Laverdière C; Chiasson S; Costea I; Moghrabi A; Krajinovic M
    Blood; 2002 Nov; 100(10):3832-4. PubMed ID: 12411325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Creatinine clearance rate and serum creatinine concentration are related to delayed methotrexate elimination in children with lymphoblastic malignancies.
    Mao J; Zhang L; Shen H; Tang Y; Song H; Zhao F; Xu W
    Neoplasma; 2014; 61(1):77-82. PubMed ID: 24195512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.
    Maiguma T; Hayashi Y; Ueshima S; Kaji H; Egawa T; Chayama K; Morishima T; Kitamura Y; Sendo T; Gomita Y; Teshima D
    Int J Clin Pharmacol Ther; 2008 Nov; 46(11):584-90. PubMed ID: 19000557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The miR-1206 microRNA variant is associated with methotrexate-induced oral mucositis in pediatric acute lymphoblastic leukemia.
    Gutierrez-Camino A; Oosterom N; den Hoed MAH; Lopez-Lopez E; Martin-Guerrero I; Pluijm SMF; Pieters R; de Jonge R; Tissing WJE; Heil SG; García-Orad A; van den Heuvel-Eibrink MM
    Pharmacogenet Genomics; 2017 Aug; 27(8):303-306. PubMed ID: 28628559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose methotrexate in Egyptian pediatric acute lymphoblastic leukemia: the impact of ABCG2 C421A genetic polymorphism on plasma levels, what is next?
    El Mesallamy HO; Rashed WM; Hamdy NM; Hamdy N
    J Cancer Res Clin Oncol; 2014 Aug; 140(8):1359-65. PubMed ID: 24718721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia.
    Lopez-Lopez E; Ballesteros J; Piñan MA; Sanchez de Toledo J; Garcia de Andoin N; Garcia-Miguel P; Navajas A; Garcia-Orad A
    Pharmacogenet Genomics; 2013 Feb; 23(2):53-61. PubMed ID: 23222202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients.
    Wang Z; Zhang N; Chen C; Chen S; Xu J; Zhou Y; Zhao X; Cui Y
    Curr Drug Metab; 2019; 20(7):592-600. PubMed ID: 31267867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: a meta-analysis.
    He HR; Liu P; He GH; Dong WH; Wang MY; Dong YL; Lu J
    Leuk Lymphoma; 2014 Dec; 55(12):2793-800. PubMed ID: 24597986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
    Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
    Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.